Table 1.

Antibodies targeting the immune system used for treatment of lung cancer.

Generic Name	Brand Name	Antibody Type	Indications and Usage Other than NSCLC	Target	Half-Life (Days)
Pembrolizumab	Keytruda	Humanized IgG4 kappa	Melanoma Small Cell Lung Cancer Head and Neck Squamous Cell Cancer Classical Hodgkin Lymphoma Primary Mediastinal Large B-Cell Lymphoma Urothelial Carcinoma MSI-H or dMMR Cancers Gastric Cancer Esophageal Cancer Cervical Cancer Hepatocellular Carcinoma Merkel Cell Carcinoma Renal Cell Carcinoma Endometrial Carcinoma Tumor Mutational Burden-High Cancer Cutaneous Squamous Cell Carcinoma	PD-1	22
Nivolumab	Opdivo	Fully human IgG4 kappa	Melanoma Small Cell Lung Cancer Head and Neck Squamous Cell Cancer Classical Hodgkin Lymphoma Urothelial Carcinoma MSI-H or dMMR colorectal cancer Hepatocellular Carcinoma Renal Cell Carcinoma Esophageal Squamous Cell Carcinoma	PD-1	25
Atezolizumab	Tecentriq	Humanized non-glycosylated IgG1 kappa	Urothelial Carcinoma Triple-Negative Breast Cancer Small Cell Lung Cancer Hepatocellular Carcinoma Melanoma	PD-L1	27
Ipilimumab	Yervoy	Fully human IgG1 kappa	Melanoma Renal Cell Carcinoma MSI-H or dMMR colorectal cancer Hepatocellular Carcinoma	CTLA-4	15
Durvalumab	Imfinzi	Fully human IgG1 kappa	Urothelial Carcinoma Small Cell Lung Cancer	PD-L1	18

PD-1: programmed death receptor-1; PD-L1: programmed cell death ligand 1; CTLA-4: cytotoxic T-lymphocyte antigen 4; MSI-H: Microsatellite Instability-High; dMMR: Mismatch Repair Deficient.